{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.1639.1639",
    "article_title": "Impact of Ruxolitinib-Response Feature on Outcome in Myelofibrosis: A Multicentre Study on 356 Patients ",
    "article_date": "December 7, 2017",
    "session_type": "634. Myeloproliferative Syndromes: Clinical: Poster I",
    "abstract_text": "Introduction. Ruxolitinib (RUX) is a JAK1/2 inhibitor able to control myelofibrosis (MF)-related splenomegaly and symptoms and improve overall-survival (OS). It is well known that long-term RUX-therapy at optimal doses contributes to clinical benefits, but impact of RUX-response feature on outcome is still relatively unknown. Aims. To report the impact of response feature on clinical outcome of 356 patients (pts) with WHO-defined MF, INT-2 or high IPSS risk, treated with RUX. Methods. A clinical database was created in 20 Italian Hematology Centres. Retrospective data on 356 MF pts treated with RUX according to prescribing information from Jan 2011 to Jun 2016 were collected. Response was defined as either one of the following at 3 (3M) and 6 (6M) months after RUX-start: reduction of splenomegaly 35% or reduction of MPN-SAF total symptom score-TSS 50% or \u22652.0 g/dL increase in hemoglobin (Hb) level. Pts were classified into four group of response: a) pts with stable response at 3M and 6M (sR); b) pts with stable non-response at 3M and 6M (sNR); c) pts with only early response at 3M (oER); pts with only late response at 6M (oLR). Survival was calculated from the start of RUX. Event-free survival (EFS) included progression to acute leukemia (AL), death and RUX discontinuation. In group comparison, the landmark approach was used at month 6 to eliminate guarantee-time bias. Results . A total of 356 (54% primary, 46% secondary to polycythemia or thrombocythemia) MF-patients were analyzed. Median age was 67 years (range 26-89) and 61% pts had a palpable splenomegaly at > 10 cm below left costal margin with a median spleen length of 11 cm. Median value of Hb and MPN-TSS were 11.1 g/dL and 20%, respectively. Median time from diagnosis to RUX-start was 16 months and median duration of RUX-therapy was 23 months. After a median of 27 months of follow-up from RUX-start, 244 patients (69%) were still receiving RUX-therapy, with 3y OS of 75% (70 deaths) and 3y EFS of 57% (16 deaths, 16 progressions to AL, 84 RUX discontinuation). Among the four group of response, we observed 229 sR, 74 sNR, 26 oER and 27 oLR. Using a 6-month landmark approach, 3y OS according to different group of response was 74%, 58%, 39%, and 70% for sR, sNR, oER and oLR, respectively. Using a Cox model adjusted for age and gender, patients oER showed a significantly worse OS respect to sR or oLR patients (HR=2.11, p=0.025) (Figure 1). Discussion. In MF-patients a RUX-response at 6M (both stable response and only late response) seems to be associated with a clinical benefit in terms of OS. Despite the cohort of pts will be certainly further enriched, these preliminary data suggest the need to continue RUX-therapy for at least 6 months. View large Download slide View large Download slide  Close modal Disclosures Bonifacio: Incyte: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Tiribelli: Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Abruzzese: Novartis: Consultancy; Incyte: Consultancy; Pfizer: Consultancy; BMS: Consultancy. Cavazzini: Incyte: Consultancy; Bristol-Meyers Squibb: Consultancy; Novartis: Consultancy; Pfizer: Consultancy. Crugnola: BMS: Honoraria; Celgene: Honoraria; Novartis: Honoraria. Vitolo: Mundipharma: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Cuneo: Gilead: Honoraria, Other: Advisory Board; Janssen: Honoraria, Other: Advisory Board; Abbvie: Honoraria, Other: Advisory Board; Roche: Honoraria, Other: Advisory Board. Breccia: Novartis: Consultancy; Bristol Myers Squibb: Consultancy; Pfizer: Consultancy; Incyte: Consultancy.",
    "topics": [
        "multicenter studies",
        "myelofibrosis",
        "ruxolitinib",
        "brachial plexus neuritis",
        "strontium",
        "splenomegaly",
        "follow-up",
        "hemoglobin",
        "leukemia, acute",
        "polycythemia"
    ],
    "author_names": [
        "Giulia Benevolo, MD",
        "Giuseppe A Palumbo, MD",
        "Massimiliano Bonifacio, MD",
        "Mario Tiribelli, MD",
        "Maura Nicolosi, MD",
        "Andrea Evangelista",
        "Bruno Martino",
        "Elisabetta Abruzzese, MD",
        "Mariella D'adda",
        "Nicola Polverelli, MD",
        "Micaela Bergamaschi, MD",
        "Alessandra Tieghi, MD",
        "Francesco Cavazzini, MD",
        "Adalberto Ibatici, MD",
        "Monica Crugnola, MD",
        "Costanza Bosi, MD",
        "Roberto Latagliata",
        "Lucia Catani, MD",
        "Franco Aversa, MD",
        "Francesco Di Raimondo, MD",
        "Umberto Vitolo, MD",
        "Roberto Massimo Lemoli, MD",
        "Renato Fanin, MD",
        "Francesco Merli",
        "Antonio Cuneo, MD",
        "Michele Cavo, MD",
        "Massimo Breccia, MD PhD",
        "Nicola Vianelli, MD",
        "Florian Heidel, MD",
        "Francesca Palandri, PhD MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Giulia Benevolo, MD",
            "author_affiliations": [
                "Hematology, Hospital, Citt\u00e0 della Salute e della Scienza, Turin, ITA "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe A Palumbo, MD",
            "author_affiliations": [
                "University of Catania, Division of Hematology, Azienda Policlinico-OUE, Catania, ITA "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimiliano Bonifacio, MD",
            "author_affiliations": [
                "Department of Medicine, Section of Haematology, University of Verona, Verona, Italy "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Tiribelli, MD",
            "author_affiliations": [
                "Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maura Nicolosi, MD",
            "author_affiliations": [
                "Hematology, Hospital, Citt\u00e0 della Salute e della Scienza, Torino, ITA "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Evangelista",
            "author_affiliations": [
                "Unit of Clinical Epidemiology and CPO, Citt\u00e0 della salute e della scienza, Turin, Italy "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bruno Martino",
            "author_affiliations": [
                "Hematology, \"Bianchi Melacrino Morelli\", Reggio Calabria, ITA "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elisabetta Abruzzese, MD",
            "author_affiliations": [
                "Hematology Unit, S.Eugenio Hospital, Tor Vergata University, Rome, ITA "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariella D'adda",
            "author_affiliations": [
                "Department of Hematology, ASST Spedali Civili di Brescia, BRESCIA, Italy "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola Polverelli, MD",
            "author_affiliations": [
                "Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Micaela Bergamaschi, MD",
            "author_affiliations": [
                "Clinical Hematology Unit, IRCCS AOU S.Martino-IST, Genova, Italy "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandra Tieghi, MD",
            "author_affiliations": [
                "Hospital of reggio emilia, Hospital, Reggio emilia, Italy "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Cavazzini, MD",
            "author_affiliations": [
                "Section of Hematology, University of Ferrara, Cona, Italy "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Adalberto Ibatici, MD",
            "author_affiliations": [
                "Azienda Ospedaliera Universitaria San Martino - IRCCS, Genova, ITA "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Monica Crugnola, MD",
            "author_affiliations": [
                "Division of Hematology, University Hospital of Parma, Parma, Italy "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Costanza Bosi, MD",
            "author_affiliations": [
                "hematology section, Hospital of Piacenza, piacenza, Italy "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberto Latagliata",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Hospital, Rome, Italy "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lucia Catani, MD",
            "author_affiliations": [
                "University of Bologna, Bologna, Italy "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Franco Aversa, MD",
            "author_affiliations": [
                "University of Perugia, Perugia, ITA "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Di Raimondo, MD",
            "author_affiliations": [
                "University of Catania, Division of Hematology, Azienda Policlinico-OUE, Catania, Italy "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Umberto Vitolo, MD",
            "author_affiliations": [
                "Dipartimento di Oncologia e Ematologia, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberto Massimo Lemoli, MD",
            "author_affiliations": [
                "Hospital, Genova, ITA "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Renato Fanin, MD",
            "author_affiliations": [
                "Azienda Ospedaliero Universitaria, Udine, ITA "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Merli",
            "author_affiliations": [
                "Arcispedale Santa Maria Nuova, UOC of Hematology, AUSL Reggio Emilia/IRCCS, Reggio Emilia, Italy "
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Cuneo, MD",
            "author_affiliations": [
                "Hematology, St. Anna University Hospital, Ferrara, Italy "
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Cavo, MD",
            "author_affiliations": [
                "Department of Physics and Astronomy, University of Bologna, Bologna, Italy "
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimo Breccia, MD PhD",
            "author_affiliations": [
                "Dipartimento Biotecnologie Cellulari, University of Rome \"Sapienza\", Roma, Italy "
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola Vianelli, MD",
            "author_affiliations": [
                "Institute of Hematology \"L. and A. Ser\u00e0gnoli\", Sant'Orsola-Malpighi University Hospital, Bologna, ITA "
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Florian Heidel, MD",
            "author_affiliations": [
                "universitatsklinikum, hematologie und onkologie, jena, Germany "
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Palandri, PhD MD",
            "author_affiliations": [
                "Department of Hematology/Oncology, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-10T04:03:44",
    "is_scraped": "1"
}